Clinuvel Pharmaceuticals (ASX:CUV) Tax Rate %: 28.38% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CUV Clinuvel Pharmaceuticals Ltd ASX:CUV
80 GF Score
Price A$10.06
GF Value A$17.80
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Tax Rate %?

Clinuvel Pharmaceuticals ASX:CUV +1.11% 80 Tax Rate % is 28.38% as of Dec. 2025. GuruFocus rates ASX:CUV with a GF Score™ of 80/100 and a GF Value™ of A$17.80 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Clinuvel Pharmaceuticals's Tax Expense for the six months ended in Dec. 2025 was A$4.14 Mil. Clinuvel Pharmaceuticals's Pre-Tax Income for the six months ended in Dec. 2025 was A$14.58 Mil. Therefore, Clinuvel Pharmaceuticals's Tax Rate % for the quarter that ended in Dec. 2025 was 28.38%.

Clinuvel Pharmaceuticals Tax Rate % Related Terms

Clinuvel Pharmaceuticals Tax Rate % Historical Data

* Premium members only.

The historical data trend for Clinuvel Pharmaceuticals's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals Tax Rate % Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.83 39.17 32.85 29.68 29.83

Clinuvel Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.14 31.15 35.82 25.40 28.38
ASX:CUV
80GF Score
Clinuvel Pharmaceuticals Ltd ASX:CUV
Tax Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinuvel Pharmaceuticals Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Clinuvel Pharmaceuticals's Tax Rate % for the fiscal year that ended in Jun. 2025 is calculated as

Tax Rate %=Tax Expense (A: Jun. 2025 )/Pre-Tax Income (A: Jun. 2025 )
=15.38/51.553
=29.83 %

Clinuvel Pharmaceuticals's Tax Rate % for the quarter that ended in Dec. 2025 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2025 )/Pre-Tax Income (Q: Dec. 2025 )
=4.139/14.582
=28.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of 28.38% mean?
Clinuvel Pharmaceuticals (ASX:CUV) has a Tax Rate % of 28.38% as of Dec. 2025.
Is Clinuvel Pharmaceuticals' Tax Rate % too high?
Clinuvel Pharmaceuticals' current Tax Rate % is 28.38%. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Tax Rate % compare to VRTX and REGN?
Clinuvel Pharmaceuticals' Tax Rate % of 28.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. Clinuvel Pharmaceuticals's current Tax Rate % is 28.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (ASX:CUV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$17.80, compared to a current price of A$10.06 — trading 43.5% below its estimated fair value. The current Tax Rate % is 28.38%. Clinuvel Pharmaceuticals' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (ASX:CUV), the current Tax Rate % is 28.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (ASX:CUV) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of A$10.06 is trading 43.5% below its estimated GF Value™ of A$17.80. GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for ASX:CUV:

  • Tax Rate %: 28.38%
  • GF Value™: A$17.80 vs. price of A$10.06 (43.5% below fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the ASX:CUV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
80GF Score

Get the complete analysis for ASX:CUV

Tax Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$10.06
Price
A$17.80
GF Value